Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
ConditionAngioedema
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorBernstein Clinical Research Center
About this trial
use of lanadelumab in patients with acquired angioedema
Eligibility criteria
Qualifiers
A diagnosis of AAE with recurrent attacks without urticaria (decreased C1INH functional, quantitative levels, decreased C4 and decreased C1q levels, no family history of angioedema), presence of anti-C1INH antibody and/or paraproteinemia (e.g. monoclonal gammopathy of unknown significance)
historical attack rate of >= on attack per month prior to starting tranexamic acid (TAA)
Disqualifiers
History of anaphylaxis or hypersensitivity to biologics
History of major systemic disease not well controlled in opinion of the PI
Women who are pregnant or breast feeding
Concurrent participation in other clinical trials
Trial design
Treatments tested in this trial
- Lanadelumab 300 mg
Treatment groups
5 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov